Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 94.35
-3.85 (-3.92%)
Sep 10, 2026, 4:08 PM HKT
Innovent Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,706 | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 |
| 15,706 | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 | |
Revenue Growth | 37.50% | 38.42% | 51.82% | 36.21% | 6.71% | 11.08% |
Cost of Revenue | 3,761 | 3,044 | 2,258 | 1,807 | 1,382 | 1,224 |
Gross Profit | 11,946 | 9,998 | 7,163 | 4,399 | 3,175 | 3,045 |
Selling, General & Admin | 7,553 | 6,640 | 5,085 | 3,851 | 3,426 | 3,426 |
Research & Development | 3,299 | 2,624 | 2,202 | 2,112 | 2,871 | 2,323 |
Operating Expenses | 10,852 | 9,264 | 7,287 | 5,963 | 6,297 | 5,749 |
Operating Income | 1,094 | 733.62 | -123.3 | -1,564 | -3,123 | -2,703 |
Interest Expense | -59.26 | -79.6 | -67.65 | -98.62 | -101.7 | -62.46 |
Interest & Investment Income | 604.57 | 438.69 | 423.45 | 452.84 | 189.54 | 151.76 |
Earnings From Equity Investments | -115.13 | -96.79 | -41.01 | - | - | - |
Currency Exchange Gain (Loss) | -276.31 | -246.83 | 130.28 | 60.82 | 752.05 | -198.75 |
Other Non Operating Income (Expenses) | 333.12 | 117.36 | 76.13 | 90 | 107.32 | 46.78 |
EBT Excluding Unusual Items | 1,581 | 866.45 | 397.91 | -1,059 | -2,176 | -2,766 |
Gain (Loss) on Sale of Investments | 4.56 | 4.56 | 179.03 | 30.81 | 5.1 | 125.02 |
Gain (Loss) on Sale of Assets | -0.57 | -0.57 | -22.99 | -0.95 | 0.06 | -0.71 |
Asset Writedown | -31.52 | -31.52 | -632.57 | -115.36 | - | - |
Pretax Income | 1,553 | 838.92 | -78.62 | -1,144 | -2,170 | -2,642 |
Income Tax Expense | 321.08 | 25.36 | 16.01 | -116.5 | 8.8 | 87.04 |
Earnings From Continuing Operations | 1,232 | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 |
Net Income | 1,232 | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 |
Net Income to Common | 1,232 | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 |
Net Income Growth | 8.84% | - | - | - | - | - |
Shares Outstanding (Basic) | 1,719 | 1,677 | 1,627 | 1,560 | 1,490 | 1,456 |
Shares Outstanding (Diluted) | 1,794 | 1,741 | 1,627 | 1,560 | 1,490 | 1,456 |
Shares Change | 7.87% | 6.98% | 4.35% | 4.67% | 2.37% | 7.27% |
EPS (Basic) | 0.72 | 0.48 | -0.06 | -0.66 | -1.46 | -1.87 |
EPS (Diluted) | 0.70 | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 |
EPS Growth | 3.15% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 9,731 | 321.36 | -971.58 | -2,816 | -3,090 |
Free Cash Flow Per Share | - | 5.59 | 0.20 | -0.62 | -1.89 | -2.12 |
Gross Margin | 76.06% | 76.66% | 76.03% | 70.89% | 69.67% | 71.32% |
Operating Margin | 6.97% | 5.63% | -1.31% | -25.20% | -68.54% | -63.31% |
Profit Margin | 7.85% | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% |
Free Cash Flow Margin | - | 74.62% | 3.41% | -15.65% | -61.80% | -72.38% |
EBITDA | 1,703 | 1,310 | 262.56 | -1,288 | -2,878 | -2,538 |
EBITDA Margin | 10.84% | 10.05% | 2.79% | -20.76% | -63.16% | -59.44% |
D&A For EBITDA | 608.77 | 576.53 | 385.86 | 275.6 | 245.09 | 165.4 |
EBIT | 1,094 | 733.62 | -123.3 | -1,564 | -3,123 | -2,703 |
EBIT Margin | 6.97% | 5.63% | -1.31% | -25.20% | -68.54% | -63.31% |
Effective Tax Rate | 20.67% | 3.02% | - | - | - | - |